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BACKGROUND: In contrast to cellular receptors, soluble
receptors do not enhance the cellular activation
because they do not have transmembranic and
cytoplasmic parts, acting thereby as endogenous
regulatory mechanisms against systemic functions
of cytokines.
Aim: To measure serum concentrations of the soluble
interleukin-2 receptor (sIL2R), soluble interleukin-4
receptor (sIL4R), soluble interleukin-6 receptor
(sIL6R), and soluble tumor necrosis factor-a receptor
I and soluble tumor necrosis factor-a receptor II,
during the perinatal and early neonatal period, in
order to evaluate their role in activation of immune
response in labor and the first days postpartum.
Methods: Soluble receptor serum concentrations
were determined by enzyme-linked immunosorbent
assay, in 45 healthy, full-termed neonates during the
first and fifth days after birth, in 25 of their mothers
(MS), in 25 samples of umbilical cords (UC) and in 25
healthy adult donors age-matched with the mothers
(controls).
Results: Soluble receptor serum concentrations
showed considerable changes during labor and early
neonatal life, being significantly higher both in MS
(except sIL6R) and in neonatal sample UC, first and
fifth days after birth, compared with controls (p B/
0.0001). Neonatal serum sIL2R and sIL6R increased
significantly from birth to the fifth day, while the
remaining receptors showed a rapid increase in the
first day (p B/0.0001), declining significantly there-
after (p B/0.0001).
Conclusion: Our findings suggest that the elevated
concentrations of all studied soluble cytokine recep-
tors reflect the activation of immune response, and
represent also regulatory protective mechanisms for
mother and fetus
/n e o n a t ea g a i n s tt h es y s t e m i c
function of cytokines during labor and early neonatal
life.
Key words: Soluble interleukin-2 receptor, Soluble inter-
leukin-4 receptor, Soluble interleukin-6 receptor, Soluble
tumor necrosis factor-a receptor I, Soluble tumor necrosis
factor-a receptor II, Neonates
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Introduction
Cytokines, like hormones, interact with specific
cellular receptors on the surface of target cells.
Cytokine receptors show high affinity with the target
molecules, and thus a small amount of cytokine is
adequate for the biological product.
In contrast to the membranic receptors, soluble
receptors do not enhance the cellular activation
because they do not have transmembranic and
cytoplasmic parts. For that reason they act as
endogenous regulatory mechanisms against the sys-
temic (mainly) function of cytokines.
1
Two types of such inhibitors or regulatory mechan-
isms have been recognized:
. the soluble receptors (type II inhibitors) that
compete with the membranic ones for cyto-
kine binding, which is a general phenom-
enon; and
. the antagonists of receptors (type I inhibitors)
that are structurally homologous with cyto-
kines and, in coupling with the receptors,
cannot transduce signals, and thus they com-
pete with cytokine’s actions (e.g. interleukin-1
antagonist).
Type II inhibitors are thought to act as stabilizers,
eliminating the systemic (harmful) activities of cyto-
kines, and amplifying their paracrine (beneficial)
activities.
2,3
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185Our study aimed to determine soluble interleukin-
2 receptor (sIL2R), soluble interleukin-4 receptor
(sIL4R), soluble interleukin-6 receptor (sIL6R) and
soluble tumor necrosis factor-a receptor I (sTNFRI)
and soluble tumor necrosis factor-a receptor II
(sTNFRII) during the perinatal and early neonatal
period, in order to evaluate their role in activation of
immune response in labor and the first days post-
partum.
Materials and methods
The Ethics Committee of our Teaching Hospital
approved the study and written informed consent
was acquired from the participating mothers and
controls with admission in the clinic. This study
comprised 45 healthy full-term, appropriate for
gestational age, neonates, born after a single uncom-
plicated pregnancy and delivery from healthy, non-
smoking mothers (age, mean9 /standard deviation
23.59 /4.2 years, range 20/40 years). Apgar scores
were in all cases ]/8 in the first and fifth minute, and
placentas were normal in appearance and weight
(mean weight 4469 /13 g). Demographic data of
participating neonates are presented in Table 1.
In the study, the 25 mothers of the neonates also
participated, as well as 25 healthy, non-pregnant,
non-smoking women aged 24.09 /4.0 years (range
21/39 years) with regular menstrual cycles, all in
periovulation, who served as controls.
Blood was drawn from controls, from mothers
(MS), before delivery (first stage of labor), from the
doubly clamped umbilical cord (UC) at delivery
(mixed arteriovenous blood), and form the neonates
in the first (1N) and fifth (5N) days postpartum. Blood
was collected in pyrogen-free tubes and was imme-
diately centrifuged after clotting; the supernatant
serum was kept frozen at  /308C until assayed.
All cytokine soluble receptors were determined by
enzyme immunoassay and enzyme-linked immuno-
sorbent assay, using commercially available Kits.
Sensitivities, inter-assay and intra-assay coefficients
of variation were, respectively: 50 pg/ml, 7.5% and
5.2% for sIL2R (Cellfree† sIL-2R; T Cell Sciences,
Cambridge, MA, USA); 5 pg/ml, 5.2% and 2.6% for
sIL4R (Quantikine† hIL-4sR; R&D Systems, MN,
USA); 250 pg/ml, 4.2% and 2.6% for sIL6R
(Quantikine† hIL-6sR; R&D Systems, MN, USA); 30
pg/ml, 3% and 2.9% for sTNFRI (Quantikine† sTNF
RI; R&D Systems, MN, USA); and 10 pg/ml, 3.5% and
2.5% for sTNFRII (Quantikine† sTNF RII; R&D
Systems).
Statistical analysis involved non-parametric tests for
sIL4R [Wilcoxon test, Spearman correlation coeffi-
cient and Kruskal/Wallis analysis of variance (AN-
OVA)] and parametric tests (t-test, Pearson’s
correlation coefficient, one-way ANOVA) for the
remaining receptors, since data presented abnormal
and normal distributions, respectively (Kolmogorov/
Smirnov test). The level pB/0.05 was considered
statistically significant.
Results
The summarized data are presented in Table 2.
Serum sIL2R concentrations in all four samples MS,
UC, 1N and 5N were significantly higher than those in
controls (pB/0.0001), showing an increased ten-
dency in neonatal samples from UC to the 5N (p B/
0.0001).
Both 1N and 5N sIL2R concentrations were con-
siderably higher in neonates born vaginally (838.29 /
204.6 U/ml and 16629 /517.8 U/ml, respectively), than
in those delivered by elective caesarean section
(591.39 /225.2 U/ml and 1165.39 /495.4 U/ml; pB/
0.01).
Serum sIL4R concentrations were markedly ele-
vated in MS, compared with those in controls (p B/
0.0001), in UC (pB/0.0005), in 1N (pB/0.03) and in
5N (pB/0.0001). MS concentrations were dependent
significantly on the mode of delivery, being higher in
cases of vaginal delivery (median 148 pg/ml, range
95/398 pg/ml) compared with those of elective
caesarean section (median 119.3 pg/ml, range 59/
235 pg/ml; pB/0.05).
Serum sIL4R concentrations were significantly
elevated in all three neonatal samples, compared
with those in controls (pB/0.0001), followed by a
marked increase in 1N (p B/0.01) and decreased also
significantly in 5N (pB/0.01).
A strong negative correlation was found between
sIL4R and interleukin-4 (IL-4) concentrations in both
neonatal samples 1N (r/ /0.48, pB/0.002) and 5N
(r/ /0.45, pB/0.0065).
Serum sIL6R values in neonatal samples showed a
significant continuous increase from UC to the 5N
samples (pB/0.002).
Serum sIL6R values in 1N and 5N were significantly
higher than in MS (pB/0.01 and pB/0.0001, respec-
tively) and controls (p B/0.01 and pB/0.0002 respec-
tively), while no significant difference was found
among UC, MS and controls.
Table 1. Demographic characteristics of neonates
Sex
Girls n/23
Boys n/22
Birthweight [mean (range)] 3352 g (2580/3950 g)
Weeks of pregnancy [mean (range)] 39.4 (38/41)
Mode of delivery
Elective caesarean section n/11
Vaginal delivery n/34
Apgar scores 8/10
E. Protonotariou et al.
186 Mediators of Inflammation Vol 12  2003A strong correlation was found between sIL6R
concentrations in UC and 1N (r/0.85, pB/0.002)
and between 1N and 5N (r/0.8, pB/0.0001).
Serum sTNFRI and sTNFRII values showed an
intense increase from UC to 1N (pB/0.0001 and
pB/0.001, respectively), decreasing significantly
thereafter from 1N to 5N (pB/0.0001 and p B/0.01,
respectively).
Serum sTNFRI and sTNFRII concentrations in MS
were significantly higher compared with those in
controls (pB/0.0005 and pB/0.02, respectively).
Moreover, a strong correlation was found among
sTNFRI concentrations in MS and 1N samples (r/
0.4, pB/0.01), and among sTNFRII between 1N and
5N samples (r/0.7, p B/0.0002).
Discussion
The development of immunity in neonates may be
visualized as a series of adaptive cellular responses to
an ever-changing and potentially hostile environ-
ment. So, the significant elevation of neonatal sIL2R
concentrations, in this study, may be attributed to the
response of the newborn immune system to a
changing internal and external environment.
Age-related changes in serum sIL2R concentrations
in healthy persons have already been documented,
and the highest values are recorded during infancy.
4
In agreement with these findings, we have previously
reported postnatal changes in serum sIL2R concen-
trations.
5
Moreover, the dependence of sIL2R on the mode of
delivery indicates that term parturition is strongly
connected with a stimulation of cytokine network,
6,7
which is directly reflected in the high receptor
neonatal values of the first and fifth days after birth.
The exact function of sIL2R is still undefined. It is
suggested that it should be an immunoregulatory
molecule, acting competitively with the membranic
receptor for binding with IL-2, and therefore sup-
presses the systemic or local immune reactions.
8 In
accordance with this immunosuppressive activity,
high amounts of this molecule were found in many
pathological conditions, which are related to inflam-
mation
9,10 and cancer.
1113 High concentrations of
sIL2R have also been recorded in transplant recipi-
ents while an exponential further increase is rated as
an early and reliable marker of graft rejection.
14
Concentrations of sIL4R were high in maternal
serum as well as in all three neonatal samples, the
highest being found in the first day after birth. Our
findings are consistent with a previous study of sIL4R
in infants, where the highest values were found in
healthy children in comparison with others suffering
from asthma or acute respiratory infection.
15
sIL4R is also found under normal conditions as
well as in allergic inflammation.
15 Its high concentra-
tions in maternal serum corroborate its production by
placenta and adjacent feto-maternal tissue.
16 Because
of its dependence on the mode of delivery, it
amplifies the beneficial influence of vaginal delivery
in the activation of the immune system.
The rise of sIL4R concentrations in neonatal serum
in the first day after birth reflects an endogenous
regulation of IL-4 activity, which is supported by the
strong negative correlation calculated between IL-4
and its receptor in neonatal samples of the first and
fifth days postpartum. Recently, there has been great
interest in using sIL4R for the safe and effective
therapy of asthma, without the use of corticoster-
oids.
1
An impressive finding of our study is the con-
current elevation in the three soluble receptors sIL6R,
sTNFRI and sTNFRII in maternal serum and neonatal
samples. In particular, a markedly continuous in-
crease of sIL6R during the early neonatal life, as with
sIL2R, was found, while a rapid elevation of sTNFRI
and sTNFRII concentrations in the first day after birth,
followed by a decline in the fifth day was estimated.
A possible explanation for this significant elevation
of all three soluble receptors during the perinatal
period might be due to their regulatory effect against
the inflammatory cytokine activity. It is well known
that inflammatory cytokines, produced during in-
flammatory and other immune processes, might
cause systemic or local toxic reactions. Considering
that, their biosynthesis and release are closely con-
trolled, and with negative feedback mechanisms their
activities are narrowed.
3
Soluble receptors, as was mentioned earlier, be-
long to the type II inhibitors, which compete with the
membranic ones for cytokine binding. They act as
protective mechanisms, against the systemic and
potentially harmful activities of cytokines, allowing
Table 2. Soluble receptor concentrations in maternal serum (MS), umbilical cord (UC), neonatal serum day 1 (1N) and
neonatal serum day 5 (5N), and in adult controls
Samples sIL2R (U/ml) sIL4R (pg/ml) sIL6R (pg/ml) STNFRI (pg/ml) sTNFRI (pg/ml)
MS (n/25) 6829 /318 132.5 (59/398) 260969 /8489 13209 /418 19399 /605
UC (n/25) 6959 /205 75.5 (39.5/12) 323459 /9043 20509 /708 31249 /792
1N (n/45) 7859 /318 100.0 (48/312) 366359 /10379 33669 /950 42419 /957
5N (n/45) 15609 /638 74.0 (30/218) 436509 /10119 21559 /613 35679 /784
Adult controls (n/45) 4879 /163 38.5 (20/88) 249269 /9682 9339 /315 13449 /290
Data presented as mean9 /standard deviation, or as mean (range).
Soluble receptors in early life
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(beneficial) actions
2,3.
Soluble sIL6R, like interleukin-6, has been histo-
chemically detected in placental trophoblast
17 in the
developing fetus, especially in fetal adrenal glands,
possibly contributing to its development.
18
Normal pregnancy is associated with increased
shedding of TNF-a receptors, particularly of p55,
which has been determined in the maternal as well as
in the fetal system.
19 Soluble p55 has also been
discovered in fetal circulation while both p55 and p75
have been considered as physiologic constituents of
term cord blood in normal pregnancies.
20 In agree-
ment with these previous reports, p55 values, as well
as p75 values in this study, rise significantly in
maternal serum during labor, reflecting a respective
elevation of their production and implication in the
process of delivery.
In contrast to the present findings, elevated p55
concentrations have been previously found in pre-
eclamptic pregnancies before initiation of labor,
compared with normal pregnancy.
21
Moreover, because the half-life of the receptors are
longer than those of TNF-a, it has been suggested
that both receptors are reliable markers of the
cytokine and immune response activation for a long
period after the normalization of TNF-a concentra-
tions.
22
Our findings support the conclusion that high
serum soluble receptor concentrations during the
perinatal and neonatal periods reflect the activation
of immune response, and also represent regulatory
protective mechanisms for the mother and fetus/
neonate against the systemic function of cytokines,
during labor and early neonatal life.
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